CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors

被引：0
|
作者：
Wang, S. [1 ,2 ]
Arribas, A. J. [3 ]
Tarantelli, C. [3 ]
Pradier, A. [1 ,2 ]
Zucca, E. [3 ]
Rossi, D. [3 ]
Simonetta, F. [1 ,2 ]
Bertoni, F. [3 ]
机构：
[1] Univ Geneva, Geneva Univ Hosp, Dept Oncol, Div Hematol, Geneva, Switzerland
[2] Translat Res Ctr Oncohaematol, Geneva, Switzerland
[3] USI, Fac Biomed Sci, Inst Oncol Res, Bellinzona, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
297
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [31] Screening Identifies Mechanisms of Drug Resistance to PI3K Inhibitors
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (11): : 1072 - 1072
  • [32] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Maria Serova
    Armand de Gramont
    Annemilaï Tijeras-Raballand
    Célia Dos Santos
    Maria Eugenia Riveiro
    Khemaies Slimane
    Sandrine Faivre
    Eric Raymond
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1297 - 1307
  • [33] Determinants of acquired resistance to PI3K/mTOR inhibition in cells refractory to EGFR inhibition.
    Koh, King Xin
    Bhattacharya, Bhaskar
    Loh, Joanne
    Ng, Hong Kiat
    Soo, Ross
    Iacopetta, Barry
    Soong, Richie
    CANCER RESEARCH, 2013, 73 (08)
  • [34] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Serova, Maria
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    Slimane, Khemaies
    Faivre, Sandrine
    Raymond, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1297 - 1307
  • [35] Wildtype RAS activity and PI3K signaling as new vulnerabilities in cells with acquired resistance to sotorasib
    Imbody, Denis
    Solanki, Hitendra S.
    Desai, Bina
    Stewart, Paul A.
    Stern, Yaakov
    Kato, Ryoji
    Majumder, Anurima
    Bridenstine, Liznair
    Xieraili, Aobuli
    Fang, Bin
    Darville, Lancia
    Kinose, Fumi
    Koomen, John M.
    Rix, Uwe
    Marusyk, Andriy
    Haura, Eric B.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [36] Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
    Tarantelli, Chiara
    Lupia, Antonio
    Stathis, Anastasios
    Bertoni, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [37] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Sapon-Cousineau, Vladimir
    Sapon-Cousineau, Sasha
    Assouline, Sarit
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (06)
  • [38] Revival of PI3K inhibitors in non-Hodgkin's lymphoma
    Batlevi, C. L.
    Younes, A.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2047 - 2049
  • [39] PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
    Vladimir Sapon-Cousineau
    Sasha Sapon-Cousineau
    Sarit Assouline
    Current Treatment Options in Oncology, 2020, 21
  • [40] Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model
    Maharaj, Kamira
    Powers, John J.
    Achille, Alex
    Pabon-Saldana, Mibel
    Fonseca, Renee
    Deng, Susan
    Miskin, Hari P.
    Maryanski, Dave
    Sahakian, Eva
    Pinilla-Ibarz, Javier
    BLOOD, 2017, 130
12345